SCHEMBL6038997

SCHEMBL6038997

CCc1ccc(S(=O)(=O)Nc2nccnc2OCc2cccnc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 3/20 0.51
KMT2A Q03164 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
SCN9A Q15858 1/20 0.49
CCR4 P51679 1/20 0.48
LMNA P02545 1/20 0.46
MEN1 O00255 1/20 0.46
TSHR P16473 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ADRB2 P07550 1/20 0.44
ADRB1 P08588 1/20 0.44
ADRB3 P13945 1/20 0.44
ADAMTS4 O75173 1/20 0.44
ALDH1A1 P00352 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038743 0.90 HTT (0.51) NAMPTKMT2ASCN9ACCR4LMNA
SCHEMBL6039013 0.88 SCN9A (0.50) NAMPTKMT2ASCN9ACCR4LMNA
SCHEMBL6039001 0.88 MEN1 (0.53) NAMPTKMT2ASCN9ACCR4MEN1
SCHEMBL6038438 0.88 CCR4 (0.54) NAMPTKMT2AL3MBTL1SCN9ACCR4
SCHEMBL6038780 0.87 KMT2A (0.59) KMT2AL3MBTL1LMNAMEN1TSHR
SCHEMBL6038733 0.87 SCN9A (0.50) NAMPTKMT2ASCN9ACCR4LMNA
SCHEMBL6038395 0.85 KDM4E (0.57) NAMPTKMT2AL3MBTL1SCN9ACCR4
SCHEMBL6038942 0.84 KMT2A (0.51) KMT2AL3MBTL1CCR4LMNAMEN1
SCHEMBL6038493 0.82 CCR4 (0.48) NAMPTKMT2ASCN9ACCR4LMNA
SCHEMBL6038732 0.81 KMT2A (0.48) KMT2AL3MBTL1LMNAMEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 NAMPT 2390/4885KMT2A 4190/4885L3MBTL1 2666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.